About eptacog alfa
Recombinant activated clotting factor VII
Used for
- Treats bleeding episodes in haemophilia A or B with inhibitors.
- Prevents bleeding during surgery in haemophilia with inhibitors.
- Treats bleeding in congenital factor VII deficiency.
- Treats bleeding in acquired haemophilia.
Usual adult dose
Usually 90 micrograms/kg intravenously every 2–3 hours until bleeding is controlled; dosing depends on the condition.
Usual dose in children
Usually 90 micrograms/kg intravenously every 2–3 hours; dosing depends on the condition.
Common side effects
- Fever
- Headache
- Nausea or vomiting
- Blood clots, including heart attack or stroke
Important warnings
- Can cause serious or life-threatening blood clots.
- Risk may be higher with other clotting medicines or certain medical conditions.
- Use requires specialist oversight and monitoring.
- Not interchangeable with other factor VII products.
Pregnancy
Use only when clearly needed; pregnancy safety information is limited.
Breastfeeding
It is unknown whether this medicine passes into breast milk; use requires clinical assessment.
Interactions
- Antifibrinolytic medicines, such as tranexamic acid, may increase clotting risk.
- Other clotting medicines, including activated prothrombin complex concentrate, may increase clotting risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.